Anti-HIV protease 抗体 [1696] (ab8327)
![Dot Blot - Anti-HIV protease antibody [1696] (ab8327)](https://www.abcam.co.jp/ps/products/8/ab8327/Images/ab8327-480290-anti-hiv-protease-antibody-dot-blot-human.jpg "Dot Blot - Anti-HIV protease antibody [1696] (ab8327)")
Key features and details
- Mouse monoclonal [1696] to HIV protease
- Suitable for: Dot blot
- Isotype: IgG1
製品の概要
-
製品名
Anti-HIV protease antibody [1696]
HIV protease 一次抗体 製品一覧 -
製品の詳細
Mouse monoclonal [1696] to HIV protease -
由来種
Mouse -
特異性
The antibody recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2). The antibody does not react with the precursor.
-
アプリケーション
適用あり: Dot blotmore details -
免疫原
Recombinant full length protein corresponding to HIV protease. Bacterially expressed full-length HIV-1 protease.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 7.40
Preservative: 0.098% Sodium azide
Constituent: 99% PBS -
Concentration information loading... -
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
1696 -
ミエローマ
unknown -
アイソタイプ
IgG1 -
研究分野
関連製品
-
Compatible Secondaries
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab8327の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Dot blot |
Use at an assay dependent concentration.
|
| 特記事項 |
|---|
|
Dot blot
Use at an assay dependent concentration. |
ターゲット情報
-
関連性
The HIV1 core consists of a viral genome housed within a conical viral capsid that is generated during virion maturation. Human immunodeficiency virus type 1 (HIV1) matures after the viral protease processes the Gag and Pol polyproteins at 10 substrate locations. The protease of HIV1 is an aspartic protease and is functional only as a dimer; dimerization results in the formation of a binding cleft in which each of the two catalytic aspartic acids in which each monomer contributes each of the 2 catalytic aspartic acids. Because the protease is active only as a dimer, two of the GagPol precursors must themselves dimerize during virus assembly so that their protease domains can dimerize, become active, and process the precursors. Both the order and kinetics of cleavage as well as the extent of precursor processing appear to be critical steps in the generation of fully infectious, appropriately assembled viral particles. Inhibition of HIV-1 protease represents an important avenue for antiviral therapy. Currently available combination chemotherapy with reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) for human immunodeficiency virus type 1 (HIV1) infection and AIDS have been shown to suppress the replication of HIV1 and extend the life expectancy of HIV1 infected individuals. -
別名
- HIV-1 protease antibody
- Human immunodeficiency virus protease antibody
- PR antibody
- Retropepsin antibody
画像
-
Dot Blot - Anti-HIV protease antibody [1696] (ab8327)
Dot blot analysis of ab8327. The total amount of ab8327 spotted on the nitrocellulose membrane are indicated in left column.
Lane 1: ab8327; 0.2 μg/ml
Lane 2: ab8327; 1.0 μg/ml
Lane 3: ab8327; 2.0 μg/ml
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (7)
ab8327 は 7 報の論文で使用されています。
- Han S et al. Continuous progression of hemorrhage of sphenoid ridge meningioma causing cerebral hernia: A case report and literature review. Oncol Lett 20:785-793 (2020). PubMed: 32566005
- Polyzos AA et al. Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice. Cell Metab 29:1258-1273.e11 (2019). PubMed: 30930170
- Matsunaga S et al. A cell-free enzymatic activity assay for the evaluation of HIV-1 drug resistance to protease inhibitors. Front Microbiol 6:1220 (2015). WB . PubMed: 26583013
- Lin PH et al. Slow immunological progression in HIV-1 CRF07_BC-infected injecting drug users. Emerg Microbes Infect 2:e83 (2013). WB . PubMed: 26038447
- O'loughlin TL et al. Diversification and Specialization of HIV Protease Function During In Vitro Evolution. Mol Biol Evol 23:764-72 (2006). WB . PubMed: 16423863
- M'Barek NB et al. HIV-2 Protease resistance defined in yeast cells. Retrovirology 3:58 (2006). WB . PubMed: 16956392
- Lescar J et al. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci 8:2686-96 (1999). PubMed: 10631984